The United States National Institute of Health has given the okay to Ivermectin as an option for use in Covid-19. One week after Dr. Paul Marik and Dr. Pierre Kory, founding members of the Front Line Covid-19 Critical Care Alliance (FLCCC), along with Dr. Andrew Hill, researcher and consultant to the World Health Organization (WHO), presented their data before the NIH Treatment Guidelines Panel, the NIH upgraded their recommendation on Ivermectin, making it an option for use in Covid-19.
This new designation upgraded the status of Ivermectin from “against” to “neither for nor against”, which is the same recommendation given to monoclonal antibodies and convalescent plasma, both widely used in the United States.
The FLCCC statements says that by the NIH no longer recommending against Ivermectin use, doctors should feel more open in prescribing Ivermectin as another therapeutic option for the treatment of Covid-19. This may clear its path towards FDA emergency use approval.
“Ivermectin is one of the world’s safest, cheapest and most widely available drugs,” noted Dr. Kory, president of the FLCCC Alliance. “The studies we presented to the NIH revealed high levels of statistical significance showing large magnitude benefit in transmission rates, need for hospitalization, and death. What’s more, the totality of trials data supporting Ivermectin is without precedent.”
Ivermectin is widely used in the Dominican Republic. Hundreds of physicians prescribe the drug to treat their patients. Nevertheless, the low-cost pharmaceutical, nevertheless, has not been included in the official Covid-19 treatment protocols by the Ministry of Public Health that follow guidelines of the US public health authorities.
Read more:
FLCCC
17 January 2021